Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2525)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5695)
  2. Department of Medicine (5685)
  3. GSK Faculty (1658)
  4. Human Oncology and Pathogenesis Program (1157)
  5. Department of Pathology and Laboratory Medicine (1129)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (785)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (203)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (689)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5695)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quantifying the effect of everolimus on both tumor growth and new metastases in metastatic renal cell carcinoma (RCC): A dynamic tumor model of the RECORD-1 phase III trial
    Meeting Abstract

    Stein, A. M.; Carter, A.; Hollaender, N.; Motzer, R. J.; Sarr, C.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A six-gene panel that predicts survival in men with castration-resistant prostate cancer
    Meeting Abstract

    Subudhi, S. K.; Heller, G.; Anand, A.; Danila, D. C.; Fleisher, M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase I dose-escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in patients (pts) with castration-resistant prostate cancer (CRPC): Final results
    Meeting Abstract

    Slovin, S. F.; Morris, S.; Kargman, M.; Durso, R.; Curley, T.; Israel, R. J.; Olson, W. C.; Murphy, D.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial
    Meeting Abstract

    Rini, B. I.; Escudier, B.; Tomczak, P.; Kaprin, A.; Hutson, T. E.; Szczylik, C.; Tarazi, J. C.; Rosbrook, B.; Kim, S.; Motzer, R. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Saad, F.; Akaza, H.; Eisenberger, M. A.; Nelson, J.; Scher, H. I.; Suzuki, K.; Wirth, M.; Webb, I. J.; Wang, J.; MacLean, D.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Borwick, L. S.; Momen, L.; Curley, T.; Arauz, G.; Larson, S. M.; Fleisher, M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Slovin, S. F.; Morris, M. J.; Steinbrecher, J. E.; Chen, Y.; Fleisher, M.; Larson, S. M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Analysis of the relationship between Karnofsky performance status (KPS) and tumor response in the RECORD-1 phase III trial of everolimus in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Porta, C.; Escudier, B.; Hutson, T. E.; Figlin, R. A.; Calvo, E.; Grünwald, V.; Osanto, S.; Ravaud, A.; Panneerselvam, A.; Knox, J. J.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Risk factor migration and survival: Analysis from international dataset of 3,748 metastatic renal cell carcinoma (mRCC) patients treated on clinical trials
    Meeting Abstract

    Patil, S.; Manola, J.; Elson, P.; Bro, W.; Negrier, S.; Escudier, B.; Bukowski, R. M.; Motzer, R. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium
    Meeting Abstract

    Milowsky, M. I.; Regazzi, A. M.; Garcia-Grossman, I. R.; Trout, A.; Flaherty, A.; Gerst, S.; Al-Ahmadie, H.; Ostrovnaya, I.; Bajorin, D. F.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save